Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced that it will report its second quarter 2026 financial results after the market close on Wednesday, July 22, 2026. The Company will ...

Turtle Creek Asset Management, an investment management company, recently published its Q1 2026 report. A copy is available to download here. Turtle Creek Asset Management’s Q1 2026 report covers key ...

Medpace (MEDP) closed the most recent trading day at $461.60, moving -1.26% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.57%. Meanwhile, the Dow ...

Clinical trials can be wildly expensive for upstart drugmakers to run, which has led to a growth industry of outsourcing to scaled expert industry players like Medpace. In 2023 and 2024, ...

In early June 2026, Medpace Holdings appointed long-time insider Brad W. Hansman as Executive Vice President, Operations, sharing principal operating officer responsibilities with Susan E. Burwig. At ...

Initiated a position in Medpace, increased investment after Q2 earnings miss; believe stock issues are temporary, presenting a buying opportunity. Medpace, a niche leader in CRO industry, operates ...

Medpace operates exclusively on a full-service basis, meaning clients hire them to run entire clinical trial phases end-to-end. The result is a business that scales through operational precision, not ...

Medpace (MEDP Quick Quote MEDP - Free Report) closed the most recent trading day at $466.80, moving +1.32% from the previous trading session. The stock's change was more than the S&P 500's daily gain ...

Medpace Holdings Inc. (NASDAQ:MEDP) posted better-than-expected third-quarter earnings on Thursday. The clinical contract research organization reported earnings of $3.86, beating the consensus of ...

Medpace (MEDP Quick Quote MEDP - Free Report) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend ...